Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy.
Emanuele CrocettiSarah CattaneoWalter BergamaschiStefano De ServiAntonio Giampiero RussoPublished in: Journal of clinical medicine (2021)
After two years of follow-up, in comparison with warfarin, NOACs users showed a significant reduction of overall mortality (all NOACs), hospital admission for myocardial infarction (apixaban and edoxaban), ischemic stroke (dabigatran) and bleeding (rivaroxaban).
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- heart failure
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- chronic kidney disease
- healthcare
- venous thromboembolism
- left ventricular
- cardiovascular events
- risk factors
- patient reported
- pulmonary embolism
- acute coronary syndrome
- adverse drug